• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Agenus stock plummets over 50% as FDA rejects accelerated approval for BOT/BAL cancer therapy

by July 18, 2024
written by July 18, 2024

Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cancer combination therapy.

Despite the setback, the company remains committed to exploring alternative pathways to bring this promising treatment to market.

The FDA’s recommendation came after Agenus presented results from its Phase 2 study, revealing a 19.4% overall response rate (ORR) and a 90% 6-month survival rate for the 75mg dosage of BOT/BAL.

However, concerns about the therapy’s survival benefits led to a sharp sell-off of Agenus stock, which had seen significant gains earlier in the year.

Dr. Steven O’Day, Agenus’ chief medical officer, emphasized the company’s determination to advance BOT/BAL, including plans to incorporate a BOT monotherapy arm in its upcoming Phase 3 trial.

This strategic move aims to address FDA concerns and pave the way for future regulatory approval.

Financial and analyst insights

Despite the stock’s recent downturn, analysts previously projected a bullish outlook for Agenus, with a consensus “buy” rating and an average price target of $39 per share.

The company’s financial resilience, including ending the first quarter with $52.9 million in cash, underscores its ability to navigate regulatory challenges while advancing its clinical pipeline.

Agenus to meet with European regulators

Looking ahead, Agenus plans strategic engagements with European regulators in the third quarter of 2024 to discuss regulatory pathways for BOT/BAL.

Additionally, the company will present compelling data on the therapy’s efficacy in treating Sarcoma at a prestigious European medical oncology event in September, highlighting its commitment to addressing unmet medical needs.

The FDA’s decision represents a critical juncture for Agenus as it strives to balance scientific innovation with regulatory scrutiny.

While the setback underscores the challenges inherent in drug development, Agenus remains steadfast in its mission to deliver innovative treatments that can potentially transform patient outcomes in oncology.

The post Agenus stock plummets over 50% as FDA rejects accelerated approval for BOT/BAL cancer therapy appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Netflix Q2 earnings preview: Wall Street awaits updates on ad-supported model
next post
Domino’s Pizza stock crashes as American consumer struggles with rising food prices

related articles

Asian markets open: Nikkei, Hang Seng fall on...

June 12, 2025

Aluminum and steel tariffs spark rise in secondary...

June 12, 2025

Airbus sees aviation boom ahead, global fleet to...

June 12, 2025

US-China trade talks and Washington’s decade-long effort to...

June 12, 2025

Europe markets open: Stoxx 600 dips as UK...

June 12, 2025

UK GDP falls by 0.3% in April as...

June 12, 2025

Gordon Brothers buys Poundland; pledges £80 mn for...

June 12, 2025

Air India plane crash: London-bound flight with 242...

June 12, 2025

Air India plane crash live update: Indian President...

June 12, 2025

Copper remains supported for now even as China...

June 12, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Biden White House has ‘very low’ trust in Netanyahu regime, urges transparency: report

    October 8, 2024
  • LG Electronics India, CATL, and other major Asian IPOs to watch out for in 2025

    January 6, 2025
  • SCOOP: Blue state Republican could oppose Trump tax bill over Medicaid changes

    June 28, 2025
  • More than 100 former GOP officials from past administrations publicly endorse Harris over Trump

    September 18, 2024
  • House Republicans zero in on Biden autopen pardons after bombshell report

    July 24, 2025

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 3

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 4

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (6,028)
  • Investing (634)
  • Stock (925)

Latest Posts

  • Oil and natural gas: Oil under pressure at 77.00 level

    July 29, 2024
  • Cotton slams Harris as ‘naive’ on Iran, blasts VP for not being tough on Hamas

    August 11, 2024
  • Trump appeared on Joe Rogan’s podcast for nearly three hours: Here are the top moments

    October 26, 2024

Recent Posts

  • Dozens of former FBI agents rally around Kash Patel’s confirmation: ‘Lives have been shattered’

    January 29, 2025
  • ‘Squad’ member delivers real-time whiteboard responses to Trump: ‘No king!’

    March 5, 2025
  • After Wednesday’s record rally, Tesla stock falls 6% today as analysts cut price targets

    April 11, 2025

Editor’s Pick

  • Trump team fires back after Dem senator declares ‘The fight is just beginning’

    January 7, 2025
  • New polls reveal which White House term showed stronger polling numbers for Trump

    March 4, 2025
  • US accuses Denmark of treating Greenlanders as ‘second-class citizens’ during Vance visit to Arctic base

    March 28, 2025
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock